{"ticker": {"uuid": "c293609b-7203-452c-9f0a-7f8bc7bfa84d", "symbol": "ARDX", "name": "Ardelyx Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNX2FqTktFTFBqbEd4X2lHMFBnTU91Sy12SVF3aTRoMUhOM1A2RkVLWjBCRkVnWkRmelFXQXB2TXNDMFcyeUNPdVNJMC00VTdjQU5lMEZzUHhNU3RNdDNkMkJjZjRnRXM3SzN5aFhuMGtWSGFSTWdYM2JoMW1xYThsNVpqd0JJM1pxZTZvaUNQT0xBWGtfX09LeE1xTTVnemVaOFFia0RCUVJHNWtP?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T23:13:00+00:00", "published_display": "15 Jul 2026 23:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (ARDX) Edition", "summary": "This article provides an analysis of Ardelyx Inc. (ARDX), highlighting weak near and mid-term sentiment that could challenge its long-term positive outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with d", "url": "https://news.stocktradersdaily.com/news_release/78/Trading_the_Move,_Not_the_Narrative:_ARDX_Edition_071526043002_1784104202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T04:30:00", "published_display": "15 Jul 2026 04:30", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ardelyx Secures New $50 Million Term F Loan", "summary": "Ardelyx (ARDX) has secured a new $50 million Term F Loan under its existing agreement with SLR Investment Corp. and other lenders to support general corporate purposes and strategic initiatives. The loan matures on July 1, 2030, with interest-only payments permitted until maturit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARDX/pressreleases/3121996/ardelyx-secures-new-50-million-term-f-loan/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T01:40:36", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030", "summary": "Ardelyx, Inc. (NASDAQ: ARDX) has secured a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders, with the funding received on June 29, 2026. This loan matures on July 1, 2030, and allows for interest-only payment", "url": "https://www.stocktitan.net/sec-filings/ARDX/8-k-ardelyx-inc-reports-material-event-00f5794e043b.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:54", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ardelyx, Inc. \u2013 NASDAQ:ARDX", "summary": "The article provides a financial overview of Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its price-to-sales forward metric. It details the company's stock market presence on Nasdaq and offers navigation to various financial tools and data through the TradingView platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T12:09:43", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx: The Market Is Right To Discount This Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSEpEVVhub3NSRHlIaXBncGVCbXFkSWduR3VRdzBCQ1VMa3c0WW8temhraE0wT3h0am9EbVlrT1pBQzQ2UHh5Wm9BbHBtR05TV3FRdnRCZDUyS2RvcVRRdVlZYkVOdDlEcFRYNmN2RXJrdXZSMWVEVlJ2OE1NSnZ0cGhNaWhxdldrYVFLVndtMDZmQTB0UWRxbWRSWjh3X0dj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Ardelyx, Inc. \u2013 NASDAQ:ARDX", "summary": "This article provides financial information for Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its \"Price to book forward\" metric. The content appears to be a stub or a section from a financial data platform, highlighting the company's stock information and financial over", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:10:36", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ardelyx, Inc. \u2013 TRADEGATE:41X", "summary": "This article provides limited financial information for Ardelyx, Inc. (TRADEGATE:41X), focusing on its forward price-to-earnings ratio. The content indicates that market data is closed with no trades, and the report offers a brief overview of financial metrics without specific va", "url": "https://www.tradingview.com/symbols/TRADEGATE-41X/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:09:12", "published_display": "01 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling", "summary": "A recent U.S. federal appellate court ruling has determined that Ardelyx's drug Xphozah will be included in Medicare's End Stage Renal Disease (ESRD) bundled payment system, rather than being reimbursed separately. This decision concludes a long-standing legal dispute and will al", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour", "source_name": "Simply Wall Street", "published_at": "2026-07-01T09:39:54", "published_display": "01 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15", "summary": "Jefferies has reiterated its Buy rating on Ardelyx (ARDX.US) and maintained its target price at $15. This indicates a continued positive outlook from the firm regarding Ardelyx's stock performance.", "url": "https://www.moomoo.com/news/post/72123741/jefferies-maintains-ardelyx-ardxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-26T19:40:52", "published_display": "26 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ)", "summary": "Ardelyx shares declined approximately 6% after losing an appeal against the Health and Human Services Department. The appeal concerned a Medicare decision that eliminated Part D coverage for Ardelyx's kidney disease therapy, Xphozah. This setback stems from a lawsuit filed in Jul", "url": "https://seekingalpha.com/news/4607819-ardelyx-falls-after-setback-xphozah-appeal", "source_name": "Seeking Alpha", "published_at": "2026-06-26T18:40:20", "published_display": "26 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX)", "summary": "Ardelyx, Inc. (NASDAQ:ARDX) stock has seen a decrease of -8.42% in the past 24 hours, with a current price of 5.55 USD, though it has increased by 52.89% over the last year. Analysts provide a future price forecast for ARDX ranging from a maximum estimate of 19.00 USD to a minimu", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:20", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. Actuals & Estimates (FWB:41X)", "summary": "This article provides financial actuals and estimates for Ardelyx, Inc. (FWB:41X), covering its income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings reports, revenue, net income, and information about the company's employe", "url": "https://www.tradingview.com/symbols/FWB-41X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:39:19", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ladenburg\u2019s IBSRELA Focus Quietly Reframing Ardelyx\u2019s (ARDX) Risk\u2011Reward Story?", "summary": "Investment bank Ladenburg initiated coverage on Ardelyx (ARDX), highlighting the growing demand for IBSRELA and continued commercial success of XPHOZAH, aligning with management's ambitious long-term revenue projections. This new coverage reinforces IBSRELA's central role as a ke", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/is-ladenburgs-ibsrela-focus-quietly-reframing-ardelyxs-ardx", "source_name": "Simply Wall Street", "published_at": "2026-06-25T18:39:19", "published_display": "25 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes ARDX has a price momentum score of 8.91 and is trading between a resistance of $6.66 and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T07:40:20", "published_display": "24 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction", "summary": "Ardelyx Chief Patient Officer Laura Williams sold 81,898 shares of Common Stock for approximately $490,000, reducing her direct holdings by 17.8% after the stock rallied 70% over the past year. The transaction, executed under a 10b5-1 trading plan, involved the exercise of stock ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/2615116/ardelyx-stock-up-70-what-to-know-about-this-490-000-insider-transaction/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T22:39:34", "published_display": "23 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What\u2019s Fueling Optimism Around Ardelyx, Inc. (ARDX)\u2019s Sales and Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcGNuNWtLSTdVWHQtU0UyT0R1WU8wbUI4VUVaaURnY29VY2x6Rko5MUQ0QVF3ZkdhcG8tR0o2TkMzdkt4d1hSWmcyckRIWVBwSG11Nl9rTEdYemw2eVo1RkNMWk4zeWdWWDNGaGpqSUhBRGEwR2tYaktOZFpJVktkeEN1RVpiNlBnTFd0X2xOai04WWJ3NEcwcVNaV3Q3Z0xGcFE?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ardelyx Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a brief announcement regarding a Form 4 filing for Ardelyx Inc., dated June 22. It provides no further details beyond the filing's existence and is accompanied by various financial market data and unrelated news headlines.", "url": "https://za.investing.com/news/stock-market-news/form-4-ardelyx-inc-for-22-june-93CH-4338473", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T05:39:34", "published_display": "23 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ardelyx-insider-sold-shares-worth-201334391.html", "source_name": "MT Newswires", "published_at": "2026-06-22T20:13:34+00:00", "published_display": "22 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx chief patient officer sells $490k in stock By Investing.com", "summary": "Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ: ARDX), sold 81,898 shares of company stock for approximately $490,487 and exercised options for 31,000 shares valued at $30,690, all under a pre-arranged 10b5-1 trading plan. The transactions occurred on June 18, ", "url": "https://ng.investing.com/news/stock-market-news/ardelyx-chief-patient-officer-sells-490k-in-stock-93CH-2568509", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T20:10:11", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options", "summary": "Ardelyx, Inc.'s Chief Patient Officer, Laura A. Williams, sold 81,898 shares of common stock at a weighted average price of $5.989 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 19, 2026. Concurrently, Williams exercised stock options to acqu", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-566153b9eb60.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:11", "published_display": "22 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx chief patient officer sells $490k in stock", "summary": "Ardelyx Inc.'s Chief Patient Officer, Laura A. Williams, sold approximately $490,487 worth of company stock while simultaneously exercising stock options valued at $30,690. These transactions occurred on June 18, 2026, under a pre-arranged 10b5-1 trading plan. The article also no", "url": "https://www.investing.com/news/insider-trading-news/ardelyx-chief-patient-officer-sells-490k-in-stock-93CH-4753628", "source_name": "Investing.com", "published_at": "2026-06-22T17:10:46", "published_display": "22 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director receives RSUs and stock options as compensation", "summary": "Ardelyx, Inc. director Muna Bhanji received 26,455 restricted stock units (RSUs) and options for 39,715 shares with an exercise price of $5.6700 per share, expiring on June 16, 2036. These equity grants were part of the company's Non-Employee Director Compensation Program. Follow", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-ac6e713e290e.html", "source_name": "Stock Titan", "published_at": "2026-06-19T16:11:29", "published_display": "19 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option", "summary": "Ardelyx director Richard J. Rodgers received new equity awards as part of the company's Non-Employee Director Compensation Program. He was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares with an exercise price of $5.67 per share. These awards inc", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-a8a272aea817.html", "source_name": "Stock Titan", "published_at": "2026-06-19T05:10:11", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Ardelyx Inc (ARDX) has an earnings forecast score of 9.27, placing it highly within the Biotechnology & Medical Research industry. Analysts have a strong buy rating for ARDX, with an average price target of $11.00 and expectations for positive revenue growth. The company's EPS fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T04:40:03", "published_display": "19 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Institutional Confidence", "summary": "Ardelyx Inc (ARDX) currently holds an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 71.25%, showing a 7.13% decrease quarter-over-quarter. Steven Cohen is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:55", "published_display": "19 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity grants to Ardelyx (ARDX) director under compensation program", "summary": "Ardelyx director David M. Mott received equity awards through the company\u2019s Non-Employee Director Compensation Program. These awards included 46,737 shares of common stock at no cash cost and a stock option for 39,715 shares with an exercise price of $5.67, expiring in 2036. The ", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-4a3a75573470.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:40:19", "published_display": "19 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director granted RSUs and 39,715-share stock option", "summary": "Ardelyx director Merdad Parsey was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares at an exercise price of $5.67, under the company's Non-Employee Director Compensation Program. These awards are equity compensation, not open-market trades. Follow", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-e4c7f975087d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:28", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants", "summary": "Ardelyx (ARDX) director Onaiza Cadoret-Manier was granted 26,455 restricted stock units (RSUs) and stock options for 39,715 shares on June 16, 2026, as part of the company's Non-Employee Director Compensation Program. Following these grants, her direct holdings in common stock to", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-ba3c331c9af3.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:39:28", "published_display": "18 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNUVJ2aUdZN01pTVBMOHRLZ09xUmxpdzZjT3JUajFkUWtkdjZ3eWJPSk9DbXVSSUZoY2NEV3F2TzMwRS1CUUM0WlBqMm9ndmlZNDJ6bV93YmVkb2tCM202Tjk5NWh3MXRfT0tPZ1dMdTJSejJmcUtRXzd5TnZDUV9QdzBiaFJGaVRraGowajhDS3lOUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNSUhWcHdNNlBadm52MTdVV2U2djFOczNDbWdUQ1JiNVFFc1dWSXdkd2E5NXQ3S0V1aDllZXcxRUxvX0ZncGZqSXlOQmIwNEE1dXhFZGJhLXhmRld5c2NrZndSZGt5NmM5dXJLclh4YW10Ql9pZVd2a2R6UjFnWDRRQzVieThSang2RUR6bFd6WWdXOFQxUUpHenlVQllKcS1i?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach", "summary": "", "url": "https://finance.yahoo.com/m/6e732c6b-33fa-3102-995b-19e6c0f2feef/ardelyx-eyes-%24500m%2B-revenue.html", "source_name": "MarketBeat", "published_at": "2026-06-04T12:04:32+00:00", "published_display": "04 Jun 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Ardelyx (ARDX)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQM2p6anV0czRUZVJhZGt4LXYzRDhOb3NRUHdsaDBLMGhUaWZBbXkyVGd2MkVPQTd6UjJySDd5ZUtOSERzQ0JqNFNJU0haTzY4b3lTU1RVMnB5NHBQZjdXZi1aeTNqRGV3bHY4SjkyVVJsWk5WVEhGNWd5cjc4STFCMkhlSU9EVjRM?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Ardelyx", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ardelyx-insider-sold-shares-worth-200905220.html", "source_name": "MT Newswires", "published_at": "2026-05-19T20:09:05+00:00", "published_display": "19 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQekNQck0yMG84OWktQW9VZE1NQ2VyX3JqbUw1X3RZNjh2czdwZTIzX3VKdjB3Sms0cDc1M2JUWjdNWGxNaXlsYlowU25kSTJhdzhyclNrWVlaTUc5cDBzYzBGVTBIZ0Zid1h5QjU4VFlHZjB4OU94M0R0ZmtfaXdLdVd4b2wtdGg1dkhUOGlrNktSWmZnenc?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTzgwODIyaHhzWXVleGJDX25HeGhhbmktRE83bzVBdHdwUFVuZHJNaXVDX0U1djVheDlKWm9VczZvOTlOR1RnMFZ2eS1aYlZITURZQ3pWVWo3MHVGODhINjhsV2RMS0RiQWREa2FGSnJoLVpWVlpvZnUySzRFSlhXc3hua1Rid0dWY2N1bDBn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNeDFJdlE1ZnozdkN0QUZKRVRjZTRDOC1QS3lFekRwNUFqazUzajdBSW9WTFdHSzVuX2lRVEJCTjZic0lUeEJaT3RPelZ2R24zUm4wZnZTQWxHc05ad2ZrZnZwQVgyaE03Njl2VHNtVEE5Nmw2V2dwTURJWV84ekZZdFhBR1BhcmZPUDBpYldPWXI4cU91NF8ySklQU0RzNGRITGc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdm0wUVlZMVRaS2QxUTRLMExUblJscElUeTd6SUNnTjlXUDQ2VUw5YU1Nd1pqaGhwMlM4RFltT19wOVJyRFFfbFlMUzZYNkllelBxWDNvbnhzQmp4NHNCSnY5NXJOUFp4VDZHYk1rNTlueWtORG5NbEVOZGY1MDk5dkx0N1hCX1ZFU2owRElWVk1vN3J1VTBVaXpZMkQxbTN1cnB0Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQanJUa1BxY1VuejlpaDdCa2dHckw2QUl1QXY2NnRKem5wcFNYTnRSaGJxaVNCRGRtYlJXMmNPX1pJNVA1ZGpmWklLN1NQamF3VmU4S0dLVV9nS2std2hzMFpmSEV4U2R5eVBSN3gzekZ6UUFpdnlIajE1N2tBUHBqbUVGN0RyU3JYU09HRldiajdRQ3lJQmNwLXhsU21nYXoy?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Ardelyx (ARDX) Pricing Reflecting Its DCF Upside After Recent Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTFJIZGNBYmdKVW1CWUFkSS10aTgydnRSd1M4LXZZem1QTE9aTTlSZDlseVBLbDRqMU04cThSZktmdWVZSFJFbm1qZjFYVktDMjB5SFZ2YmdlS2JZLTlXSzRtdk5HU0FTRGU0UTBUaFJUcGlpWjYtSlF1eVp4YzZJZHdPU2pZWm9JeEVNdUFOR1dQN3Fualllek5vTEI?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx President and CEO Sells 41,000 Shares for $243,000", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNc3lIQUQ2aWJZS2NmUEl4UVAtR2o4aFlYRTI1UEVJMlo4ZW5zV3ZTbm0wbUt2MWIwaENlaF9zWW92OUNMU2pwQW8wZnNPVG1mX2hkRm9iWEJfMDV5SW9TR3l5QlhMZ1dVRllZMDhoQ1VueXdCVG9GTW94N01SSHFwOXZYZHNSOERJWkJxSmtSNUtZN0w0SzNqV2pYZUhYaS1vb24wX0FKcEtQZXYyVnBZ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Millions of women suffer IBS-C in silence; LPGA and Ardelyx team up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPVlRCSEtZM2hTMGxVdEtlY1hJQ3lIM29BcVFJNEQ5U0hVZHlwX1d2NGtuODd0cWotMkhhdHhnRWF5Y1RJZDl5eEtvVmlnR2FzZThyeHBmd2FvOFNjajl0S3FhRnVmd3k5bjgwd2NiSXNmSU91MEE2TWJDVlJmdnFUWkJIX2FXWVFXWjdCcEh3RDVhaXdENXZnenFtUkxWTXlzTHk1M3piVnhRTmVUUTNHbTQyaHJ4YXRtRV9OY3BhMms?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNOXphZFVFN3dPc1FDLXhFV212VHBXb3hTTlJtV0dqUndNcUwxUVk0cVJBc3FJVWFTTFBwVGY4SG5Oa2xMcjFOSndkamVmRzAyQ3lfc1ZFS2NFbWNWVnVVZ0h3VGxkNi1nWG44ZVlTY2pELWRUdGZnVjNpYl9GVW9iUmExTHhQSy1PalpWRk01cWJ0VnI4VllpRVFkM0xJUDBKVWlpZHU2YVJKMEpJX0lzQm9JbzNxbUpwcFQyd25xOEowWVhhRGE5ZFd0Q1o3NThpSG4tdU1xUl_SAd4BQVVfeXFMTXRNeVdlWk85ME1pMWpDd0NpT2x5bmEyNDl5ZFIwYTEtZUhfM0JXMDFITlJabXBNakx4MEZHcmczYVJDdEZxX1h3alFWSXE4MHdKclZPbXdkWW5YZHZDUXB3NTctSExiTjdZa1J3WW9aN244OWdBSTJxbGpSRGJzMTZqVnh2Q2Fzc1ZIa2M1XzNxVXVXQl9TRkhCc016cmdiWGZqb3l3UUZoOUYwaHlMTlVRS2EwSFVNRlpqOUEwTTB3QWJPME5YMnpOWUlHeHVndVlNenVFVmdVOUE2X2VB?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise \u20b95,000 crore via QIP", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQM1JXY01TZUc5cG52ekNrWFJSUnlIYS1za1pyYi10Z2NRWE5nbnRwVGpVejVpZW14QXRvVk5icEcyZTd5ajd5NXdSMjhDTFo3OFV2Vnhxbk8wV2tKUkVsaXFBMEFmWUZzX3FZQ1I3S3BndHFMaGZGeE1URENuVkFNcTFDX0NQemlVWjZfaDFKZHNDZzNLYkJnRGN2cFAtN3pZYWJjenQzMmtNOVlqc1U2TTFJTXJEbG12a202akl5ZER2d015RzAya090ZFFuYVh3dlFrc3lERzEzTjRmYlM1MW9YY1ZqR1MxUWc?oc=5", "source_name": "scanx.trade", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside \u2014 Says Constipation Drug \u2018Stole The Show\u2019 With 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcEhkRlFzbUdUbEZneW5RMXYwTE9TbWFRU3NNdEVDS21fSHFlNF9GdDQ0T05NcjRfMmpiRXdQN3FaenBUS1pQWjh2TE1rWWo1bjN3dkYwdV8xMnJoVTdSNzJEclBfWjVrSlJoTkJZTk1WT1paMlhQcWtNcFktdlA2M2xWTDNJcDU3YTVLUUJDTjBBNWUzb3hmNzA4QW5QMVBYX0VtcTVFRmxRSWhBRnY2YWd2NVZubURfTkhrMEswaW0?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Is Rallying \u2013 What Is Making Retail So Bullish?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNaU9JM3JqZDVsNzhFZUdKMWV5T3c1bHl1LVNKM1lXWTg2WVZZNWRSUmpsc2QtbEJ6S3J5cEhLWktXN3RURHE0MVRMejlSSjFnWndyMXE0SVNoQUdNbDhoMDFxV0pSQkV0SnZlUG1TNDBhZUU5YzlQZTg4SURRN3R1NnFqbGM3YnNYVkxpQjdHLU9UMHUtbzhySHB5LVN3aHFiMmxjY0NEMGw0a2ZmSFJUMWp1ZUFPczRzOUkyOUpUU0ZHM3Fjd3pVZUlkbFRfQjBMbk5Tdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-08T17:01:54+00:00", "published_display": "08 Jan 2026 17:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc.'s (NASDAQ:ARDX) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNX2FqTktFTFBqbEd4X2lHMFBnTU91Sy12SVF3aTRoMUhOM1A2RkVLWjBCRkVnWkRmelFXQXB2TXNDMFcyeUNPdVNJMC00VTdjQU5lMEZzUHhNU3RNdDNkMkJjZjRnRXM3SzN5aFhuMGtWSGFSTWdYM2JoMW1xYThsNVpqd0JJM1pxZTZvaUNQT0xBWGtfX09LeE1xTTVnemVaOFFia0RCUVJHNWtP?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T23:13:00+00:00", "published_display": "15 Jul 2026 23:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading the Move, Not the Narrative: (ARDX) Edition", "summary": "This article provides an analysis of Ardelyx Inc. (ARDX), highlighting weak near and mid-term sentiment that could challenge its long-term positive outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with d", "url": "https://news.stocktradersdaily.com/news_release/78/Trading_the_Move,_Not_the_Narrative:_ARDX_Edition_071526043002_1784104202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T04:30:00", "published_display": "15 Jul 2026 04:30", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Secures New $50 Million Term F Loan", "summary": "Ardelyx (ARDX) has secured a new $50 million Term F Loan under its existing agreement with SLR Investment Corp. and other lenders to support general corporate purposes and strategic initiatives. The loan matures on July 1, 2030, with interest-only payments permitted until maturit", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ARDX/pressreleases/3121996/ardelyx-secures-new-50-million-term-f-loan/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T01:40:36", "published_display": "08 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030", "summary": "Ardelyx, Inc. (NASDAQ: ARDX) has secured a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders, with the funding received on June 29, 2026. This loan matures on July 1, 2030, and allows for interest-only payment", "url": "https://www.stocktitan.net/sec-filings/ARDX/8-k-ardelyx-inc-reports-material-event-00f5794e043b.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:39:54", "published_display": "02 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ardelyx, Inc. \u2013 NASDAQ:ARDX", "summary": "The article provides a financial overview of Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its price-to-sales forward metric. It details the company's stock market presence on Nasdaq and offers navigation to various financial tools and data through the TradingView platfo", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T12:09:43", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx: The Market Is Right To Discount This Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSEpEVVhub3NSRHlIaXBncGVCbXFkSWduR3VRdzBCQ1VMa3c0WW8temhraE0wT3h0am9EbVlrT1pBQzQ2UHh5Wm9BbHBtR05TV3FRdnRCZDUyS2RvcVRRdVlZYkVOdDlEcFRYNmN2RXJrdXZSMWVEVlJ2OE1NSnZ0cGhNaWhxdldrYVFLVndtMDZmQTB0UWRxbWRSWjh3X0dj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Ardelyx, Inc. \u2013 NASDAQ:ARDX", "summary": "This article provides financial information for Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its \"Price to book forward\" metric. The content appears to be a stub or a section from a financial data platform, highlighting the company's stock information and financial over", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:10:36", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ardelyx, Inc. \u2013 TRADEGATE:41X", "summary": "This article provides limited financial information for Ardelyx, Inc. (TRADEGATE:41X), focusing on its forward price-to-earnings ratio. The content indicates that market data is closed with no trades, and the report offers a brief overview of financial metrics without specific va", "url": "https://www.tradingview.com/symbols/TRADEGATE-41X/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:09:12", "published_display": "01 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling", "summary": "A recent U.S. federal appellate court ruling has determined that Ardelyx's drug Xphozah will be included in Medicare's End Stage Renal Disease (ESRD) bundled payment system, rather than being reimbursed separately. This decision concludes a long-standing legal dispute and will al", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/ardelyx-ardx-faces-new-medicare-rules-for-xphozah-after-cour", "source_name": "Simply Wall Street", "published_at": "2026-07-01T09:39:54", "published_display": "01 Jul 2026 09:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15", "summary": "Jefferies has reiterated its Buy rating on Ardelyx (ARDX.US) and maintained its target price at $15. This indicates a continued positive outlook from the firm regarding Ardelyx's stock performance.", "url": "https://www.moomoo.com/news/post/72123741/jefferies-maintains-ardelyx-ardxus-with-buy-rating-maintains-target-price", "source_name": "Moomoo", "published_at": "2026-06-26T19:40:52", "published_display": "26 Jun 2026 19:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ)", "summary": "Ardelyx shares declined approximately 6% after losing an appeal against the Health and Human Services Department. The appeal concerned a Medicare decision that eliminated Part D coverage for Ardelyx's kidney disease therapy, Xphozah. This setback stems from a lawsuit filed in Jul", "url": "https://seekingalpha.com/news/4607819-ardelyx-falls-after-setback-xphozah-appeal", "source_name": "Seeking Alpha", "published_at": "2026-06-26T18:40:20", "published_display": "26 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX)", "summary": "Ardelyx, Inc. (NASDAQ:ARDX) stock has seen a decrease of -8.42% in the past 24 hours, with a current price of 5.55 USD, though it has increased by 52.89% over the last year. Analysts provide a future price forecast for ARDX ranging from a maximum estimate of 19.00 USD to a minimu", "url": "https://www.tradingview.com/symbols/NASDAQ-ARDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:20", "published_display": "26 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. Actuals & Estimates (FWB:41X)", "summary": "This article provides financial actuals and estimates for Ardelyx, Inc. (FWB:41X), covering its income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings reports, revenue, net income, and information about the company's employe", "url": "https://www.tradingview.com/symbols/FWB-41X/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:39:19", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ladenburg\u2019s IBSRELA Focus Quietly Reframing Ardelyx\u2019s (ARDX) Risk\u2011Reward Story?", "summary": "Investment bank Ladenburg initiated coverage on Ardelyx (ARDX), highlighting the growing demand for IBSRELA and continued commercial success of XPHOZAH, aligning with management's ambitious long-term revenue projections. This new coverage reinforces IBSRELA's central role as a ke", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ardx/ardelyx/news/is-ladenburgs-ibsrela-focus-quietly-reframing-ardelyxs-ardx", "source_name": "Simply Wall Street", "published_at": "2026-06-25T18:39:19", "published_display": "25 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes ARDX has a price momentum score of 8.91 and is trading between a resistance of $6.66 and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/technical", "source_name": "TradingKey", "published_at": "2026-06-24T07:40:20", "published_display": "24 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction", "summary": "Ardelyx Chief Patient Officer Laura Williams sold 81,898 shares of Common Stock for approximately $490,000, reducing her direct holdings by 17.8% after the stock rallied 70% over the past year. The transaction, executed under a 10b5-1 trading plan, involved the exercise of stock ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/2615116/ardelyx-stock-up-70-what-to-know-about-this-490-000-insider-transaction/", "source_name": "The Globe and Mail", "published_at": "2026-06-23T22:39:34", "published_display": "23 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What\u2019s Fueling Optimism Around Ardelyx, Inc. (ARDX)\u2019s Sales and Pipeline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcGNuNWtLSTdVWHQtU0UyT0R1WU8wbUI4VUVaaURnY29VY2x6Rko5MUQ0QVF3ZkdhcG8tR0o2TkMzdkt4d1hSWmcyckRIWVBwSG11Nl9rTEdYemw2eVo1RkNMWk4zeWdWWDNGaGpqSUhBRGEwR2tYaktOZFpJVktkeEN1RVpiNlBnTFd0X2xOai04WWJ3NEcwcVNaV3Q3Z0xGcFE?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ardelyx Inc For: 22 June By Investing.com", "summary": "This article from Investing.com is a brief announcement regarding a Form 4 filing for Ardelyx Inc., dated June 22. It provides no further details beyond the filing's existence and is accompanied by various financial market data and unrelated news headlines.", "url": "https://za.investing.com/news/stock-market-news/form-4-ardelyx-inc-for-22-june-93CH-4338473", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T05:39:34", "published_display": "23 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ardelyx-insider-sold-shares-worth-201334391.html", "source_name": "MT Newswires", "published_at": "2026-06-22T20:13:34+00:00", "published_display": "22 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx chief patient officer sells $490k in stock By Investing.com", "summary": "Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ: ARDX), sold 81,898 shares of company stock for approximately $490,487 and exercised options for 31,000 shares valued at $30,690, all under a pre-arranged 10b5-1 trading plan. The transactions occurred on June 18, ", "url": "https://ng.investing.com/news/stock-market-news/ardelyx-chief-patient-officer-sells-490k-in-stock-93CH-2568509", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T20:10:11", "published_display": "22 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options", "summary": "Ardelyx, Inc.'s Chief Patient Officer, Laura A. Williams, sold 81,898 shares of common stock at a weighted average price of $5.989 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 19, 2026. Concurrently, Williams exercised stock options to acqu", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-566153b9eb60.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:10:11", "published_display": "22 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx chief patient officer sells $490k in stock", "summary": "Ardelyx Inc.'s Chief Patient Officer, Laura A. Williams, sold approximately $490,487 worth of company stock while simultaneously exercising stock options valued at $30,690. These transactions occurred on June 18, 2026, under a pre-arranged 10b5-1 trading plan. The article also no", "url": "https://www.investing.com/news/insider-trading-news/ardelyx-chief-patient-officer-sells-490k-in-stock-93CH-4753628", "source_name": "Investing.com", "published_at": "2026-06-22T17:10:46", "published_display": "22 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director receives RSUs and stock options as compensation", "summary": "Ardelyx, Inc. director Muna Bhanji received 26,455 restricted stock units (RSUs) and options for 39,715 shares with an exercise price of $5.6700 per share, expiring on June 16, 2036. These equity grants were part of the company's Non-Employee Director Compensation Program. Follow", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-ac6e713e290e.html", "source_name": "Stock Titan", "published_at": "2026-06-19T16:11:29", "published_display": "19 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option", "summary": "Ardelyx director Richard J. Rodgers received new equity awards as part of the company's Non-Employee Director Compensation Program. He was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares with an exercise price of $5.67 per share. These awards inc", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-a8a272aea817.html", "source_name": "Stock Titan", "published_at": "2026-06-19T05:10:11", "published_display": "19 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Ardelyx Inc (ARDX) has an earnings forecast score of 9.27, placing it highly within the Biotechnology & Medical Research industry. Analysts have a strong buy rating for ARDX, with an average price target of $11.00 and expectations for positive revenue growth. The company's EPS fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T04:40:03", "published_display": "19 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Inc (ARDX) Institutional Confidence", "summary": "Ardelyx Inc (ARDX) currently holds an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 71.25%, showing a 7.13% decrease quarter-over-quarter. Steven Cohen is the largest instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ardx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:55", "published_display": "19 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity grants to Ardelyx (ARDX) director under compensation program", "summary": "Ardelyx director David M. Mott received equity awards through the company\u2019s Non-Employee Director Compensation Program. These awards included 46,737 shares of common stock at no cash cost and a stock option for 39,715 shares with an exercise price of $5.67, expiring in 2036. The ", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-4a3a75573470.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:40:19", "published_display": "19 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director granted RSUs and 39,715-share stock option", "summary": "Ardelyx director Merdad Parsey was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares at an exercise price of $5.67, under the company's Non-Employee Director Compensation Program. These awards are equity compensation, not open-market trades. Follow", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-e4c7f975087d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:28", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants", "summary": "Ardelyx (ARDX) director Onaiza Cadoret-Manier was granted 26,455 restricted stock units (RSUs) and stock options for 39,715 shares on June 16, 2026, as part of the company's Non-Employee Director Compensation Program. Following these grants, her direct holdings in common stock to", "url": "https://www.stocktitan.net/sec-filings/ARDX/form-4-ardelyx-inc-insider-trading-activity-ba3c331c9af3.html", "source_name": "Stock Titan", "published_at": "2026-06-18T19:39:28", "published_display": "18 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNUVJ2aUdZN01pTVBMOHRLZ09xUmxpdzZjT3JUajFkUWtkdjZ3eWJPSk9DbXVSSUZoY2NEV3F2TzMwRS1CUUM0WlBqMm9ndmlZNDJ6bV93YmVkb2tCM202Tjk5NWh3MXRfT0tPZ1dMdTJSejJmcUtRXzd5TnZDUV9QdzBiaFJGaVRraGowajhDS3lOUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNSUhWcHdNNlBadm52MTdVV2U2djFOczNDbWdUQ1JiNVFFc1dWSXdkd2E5NXQ3S0V1aDllZXcxRUxvX0ZncGZqSXlOQmIwNEE1dXhFZGJhLXhmRld5c2NrZndSZGt5NmM5dXJLclh4YW10Ql9pZVd2a2R6UjFnWDRRQzVieThSang2RUR6bFd6WWdXOFQxUUpHenlVQllKcS1i?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach", "summary": "", "url": "https://finance.yahoo.com/m/6e732c6b-33fa-3102-995b-19e6c0f2feef/ardelyx-eyes-%24500m%2B-revenue.html", "source_name": "MarketBeat", "published_at": "2026-06-04T12:04:32+00:00", "published_display": "04 Jun 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Ardelyx (ARDX)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQM2p6anV0czRUZVJhZGt4LXYzRDhOb3NRUHdsaDBLMGhUaWZBbXkyVGd2MkVPQTd6UjJySDd5ZUtOSERzQ0JqNFNJU0haTzY4b3lTU1RVMnB5NHBQZjdXZi1aeTNqRGV3bHY4SjkyVVJsWk5WVEhGNWd5cjc4STFCMkhlSU9EVjRM?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Ardelyx", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ardelyx-insider-sold-shares-worth-200905220.html", "source_name": "MT Newswires", "published_at": "2026-05-19T20:09:05+00:00", "published_display": "19 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQekNQck0yMG84OWktQW9VZE1NQ2VyX3JqbUw1X3RZNjh2czdwZTIzX3VKdjB3Sms0cDc1M2JUWjdNWGxNaXlsYlowU25kSTJhdzhyclNrWVlaTUc5cDBzYzBGVTBIZ0Zid1h5QjU4VFlHZjB4OU94M0R0ZmtfaXdLdVd4b2wtdGg1dkhUOGlrNktSWmZnenc?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTzgwODIyaHhzWXVleGJDX25HeGhhbmktRE83bzVBdHdwUFVuZHJNaXVDX0U1djVheDlKWm9VczZvOTlOR1RnMFZ2eS1aYlZITURZQ3pWVWo3MHVGODhINjhsV2RMS0RiQWREa2FGSnJoLVpWVlpvZnUySzRFSlhXc3hua1Rid0dWY2N1bDBn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNeDFJdlE1ZnozdkN0QUZKRVRjZTRDOC1QS3lFekRwNUFqazUzajdBSW9WTFdHSzVuX2lRVEJCTjZic0lUeEJaT3RPelZ2R24zUm4wZnZTQWxHc05ad2ZrZnZwQVgyaE03Njl2VHNtVEE5Nmw2V2dwTURJWV84ekZZdFhBR1BhcmZPUDBpYldPWXI4cU91NF8ySklQU0RzNGRITGc?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdm0wUVlZMVRaS2QxUTRLMExUblJscElUeTd6SUNnTjlXUDQ2VUw5YU1Nd1pqaGhwMlM4RFltT19wOVJyRFFfbFlMUzZYNkllelBxWDNvbnhzQmp4NHNCSnY5NXJOUFp4VDZHYk1rNTlueWtORG5NbEVOZGY1MDk5dkx0N1hCX1ZFU2owRElWVk1vN3J1VTBVaXpZMkQxbTN1cnB0Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate Gap", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQanJUa1BxY1VuejlpaDdCa2dHckw2QUl1QXY2NnRKem5wcFNYTnRSaGJxaVNCRGRtYlJXMmNPX1pJNVA1ZGpmWklLN1NQamF3VmU4S0dLVV9nS2std2hzMFpmSEV4U2R5eVBSN3gzekZ6UUFpdnlIajE1N2tBUHBqbUVGN0RyU3JYU09HRldiajdRQ3lJQmNwLXhsU21nYXoy?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ardelyx (ARDX) Pricing Reflecting Its DCF Upside After Recent Share Price Swings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTFJIZGNBYmdKVW1CWUFkSS10aTgydnRSd1M4LXZZem1QTE9aTTlSZDlseVBLbDRqMU04cThSZktmdWVZSFJFbm1qZjFYVktDMjB5SFZ2YmdlS2JZLTlXSzRtdk5HU0FTRGU0UTBUaFJUcGlpWjYtSlF1eVp4YzZJZHdPU2pZWm9JeEVNdUFOR1dQN3Fualllek5vTEI?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx President and CEO Sells 41,000 Shares for $243,000", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNc3lIQUQ2aWJZS2NmUEl4UVAtR2o4aFlYRTI1UEVJMlo4ZW5zV3ZTbm0wbUt2MWIwaENlaF9zWW92OUNMU2pwQW8wZnNPVG1mX2hkRm9iWEJfMDV5SW9TR3l5QlhMZ1dVRllZMDhoQ1VueXdCVG9GTW94N01SSHFwOXZYZHNSOERJWkJxSmtSNUtZN0w0SzNqV2pYZUhYaS1vb24wX0FKcEtQZXYyVnBZ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millions of women suffer IBS-C in silence; LPGA and Ardelyx team up", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPVlRCSEtZM2hTMGxVdEtlY1hJQ3lIM29BcVFJNEQ5U0hVZHlwX1d2NGtuODd0cWotMkhhdHhnRWF5Y1RJZDl5eEtvVmlnR2FzZThyeHBmd2FvOFNjajl0S3FhRnVmd3k5bjgwd2NiSXNmSU91MEE2TWJDVlJmdnFUWkJIX2FXWVFXWjdCcEh3RDVhaXdENXZnenFtUkxWTXlzTHk1M3piVnhRTmVUUTNHbTQyaHJ4YXRtRV9OY3BhMms?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNOXphZFVFN3dPc1FDLXhFV212VHBXb3hTTlJtV0dqUndNcUwxUVk0cVJBc3FJVWFTTFBwVGY4SG5Oa2xMcjFOSndkamVmRzAyQ3lfc1ZFS2NFbWNWVnVVZ0h3VGxkNi1nWG44ZVlTY2pELWRUdGZnVjNpYl9GVW9iUmExTHhQSy1PalpWRk01cWJ0VnI4VllpRVFkM0xJUDBKVWlpZHU2YVJKMEpJX0lzQm9JbzNxbUpwcFQyd25xOEowWVhhRGE5ZFd0Q1o3NThpSG4tdU1xUl_SAd4BQVVfeXFMTXRNeVdlWk85ME1pMWpDd0NpT2x5bmEyNDl5ZFIwYTEtZUhfM0JXMDFITlJabXBNakx4MEZHcmczYVJDdEZxX1h3alFWSXE4MHdKclZPbXdkWW5YZHZDUXB3NTctSExiTjdZa1J3WW9aN244OWdBSTJxbGpSRGJzMTZqVnh2Q2Fzc1ZIa2M1XzNxVXVXQl9TRkhCc016cmdiWGZqb3l3UUZoOUYwaHlMTlVRS2EwSFVNRlpqOUEwTTB3QWJPME5YMnpOWUlHeHVndVlNenVFVmdVOUE2X2VB?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise \u20b95,000 crore via QIP", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQM1JXY01TZUc5cG52ekNrWFJSUnlIYS1za1pyYi10Z2NRWE5nbnRwVGpVejVpZW14QXRvVk5icEcyZTd5ajd5NXdSMjhDTFo3OFV2Vnhxbk8wV2tKUkVsaXFBMEFmWUZzX3FZQ1I3S3BndHFMaGZGeE1URENuVkFNcTFDX0NQemlVWjZfaDFKZHNDZzNLYkJnRGN2cFAtN3pZYWJjenQzMmtNOVlqc1U2TTFJTXJEbG12a202akl5ZER2d015RzAya090ZFFuYVh3dlFrc3lERzEzTjRmYlM1MW9YY1ZqR1MxUWc?oc=5", "source_name": "scanx.trade", "published_at": "2026-01-19T08:00:00+00:00", "published_display": "19 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside \u2014 Says Constipation Drug \u2018Stole The Show\u2019 With 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcEhkRlFzbUdUbEZneW5RMXYwTE9TbWFRU3NNdEVDS21fSHFlNF9GdDQ0T05NcjRfMmpiRXdQN3FaenBUS1pQWjh2TE1rWWo1bjN3dkYwdV8xMnJoVTdSNzJEclBfWjVrSlJoTkJZTk1WT1paMlhQcWtNcFktdlA2M2xWTDNJcDU3YTVLUUJDTjBBNWUzb3hmNzA4QW5QMVBYX0VtcTVFRmxRSWhBRnY2YWd2NVZubURfTkhrMEswaW0?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx Stock Is Rallying \u2013 What Is Making Retail So Bullish?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNaU9JM3JqZDVsNzhFZUdKMWV5T3c1bHl1LVNKM1lXWTg2WVZZNWRSUmpsc2QtbEJ6S3J5cEhLWktXN3RURHE0MVRMejlSSjFnWndyMXE0SVNoQUdNbDhoMDFxV0pSQkV0SnZlUG1TNDBhZUU5YzlQZTg4SURRN3R1NnFqbGM3YnNYVkxpQjdHLU9UMHUtbzhySHB5LVN3aHFiMmxjY0NEMGw0a2ZmSFJUMWp1ZUFPczRzOUkyOUpUU0ZHM3Fjd3pVZUlkbFRfQjBMbk5Tdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-08T17:01:54+00:00", "published_display": "08 Jan 2026 17:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ardelyx, Inc.'s (NASDAQ:ARDX) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 63, "sentiment_summary": {"positive": 15, "negative": 5, "neutral": 43, "score": 52, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 21.25, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 9.01, "count": 18}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 5.28, "latest_week": "2026-07-10", "one_week_move": 0.2, "four_week_move": -7.2, "twelve_week_move": -18.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.357253, "market_dynamics_buy_signal": false, "relative_strength": -23.978881, "fair_value_gap": -8.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.5721, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.2% over one week, -7.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "The Globe and Mail", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 18}, {"label": "Guidance", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.2% over one week, -7.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed"}], "updated_at": "2026-07-17T00:24:45.031097+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}